1. Home
  2. PETZ vs SNGX Comparison

PETZ vs SNGX Comparison

Compare PETZ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TDH Holdings Inc.

PETZ

TDH Holdings Inc.

HOLD

Current Price

$1.12

Market Cap

10.4M

Sector

Industrials

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.37

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETZ
SNGX
Founded
2002
1987
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
11.2M
IPO Year
2017
2006

Fundamental Metrics

Financial Performance
Metric
PETZ
SNGX
Price
$1.12
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
2.4K
1.6M
Earning Date
04-20-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$0.28
52 Week High
$1.68
$6.23

Technical Indicators

Market Signals
Indicator
PETZ
SNGX
Relative Strength Index (RSI) 56.90 32.25
Support Level $1.08 $0.28
Resistance Level $1.19 $1.48
Average True Range (ATR) 0.06 0.04
MACD 0.01 0.02
Stochastic Oscillator 47.63 69.92

Price Performance

Historical Comparison
PETZ
SNGX

About PETZ TDH Holdings Inc.

TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: